SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on July 5, 2002; DOI 10.1182/blood-2002-03-0734. This Article Abstract Full Text (PDF) All Versions of this Article: 2002-03-0734v1 100/10/3656    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Ingram, D. A. Articles by Kapur, R. Search for Related Content PubMed PubMed Citation Articles by Ingram, D. A. Articles by Kapur, R. Related Collections Hematopoiesis and Stem Cells Immunobiology Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 15 November 2002, Vol. 100, No. 10, pp. 3656-3662 IMMUNOBIOLOGY Lymphoproliferative defects in mice lacking the expression of neurofibromin: functional and biochemical consequences of Nf1 deficiency in T-cell development and function David A. Ingram, Lei Zhang, Jennifer McCarthy, Mary Jo Wenning, Lucy Fisher, Feng-Chun Yang, D. Wade Clapp, and Reuben Kapur From the Section of Neonatal-Perinatal Medicine, Department of Pediatrics, Herman B. Wells Center for Pediatric Research and the Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN.     Abstract Top Abstract Introduction Materials and methods Results Discussion References Ras plays an essential role in lymphocyte development and function. However, in vivo consequence(s) of regulation of Ras activity by guanosine triphosphatase (GTPase)-activating proteins (GAPs) on lymphocyte development and function are not known. In this study we demonstrate that neurofibromin, the protein encoded by the NF1 tumor suppressor gene functions as a GAP for Ras in T cells. Loss of Nf1 in T cells results in enhanced Ras activation, which is associated with thymic and splenic hyperplasia, and an increase in the absolute number of immature and mature T-cell subsets compared with control mice. Interestingly, in spite of a profound T-cell expansion and higher thymidine incorporation in unstimulated Nf1-deficient T cells, T-cell receptor and interleukin-2 receptor-mediated proliferation of thymocytes and mature T cells was substantially reduced compared with control mice. Collectively, these results identify neurofibromin as a GAP for Ras in T cells for maintaining immune homeostasis in vivo. (Blood. 2002;100:3656-3662) © 2002 by The American Society of Hematology.     Introduction Top Abstract Introduction Materials and methods Results Discussion References In lymphocytes, engagement of antigen and cytokine receptors results in the activation of multiple signaling pathways. The simultaneous activation of these pathways enhances the efficient transcription of genes encoding cytokines and cytokine receptors, necessary for further activation, proliferation, and maturation of lymphocytes.1 One of these signaling pathways involves the activation of a small GTPase, Ras. Ras is rapidly activated in antigen and cytokine receptor-stimulated lymphocytes, resulting in the activation of multiple downstream effector pathways, including transcription factors, involved in cytokine gene induction and development of T and B cells.1 The guanine nucleotide binding cycle of Ras is controlled by guanine nucleotide exchange factors (GEFs) that promote the transition from the guanosine diphosphate (GDP)-bound state to the active guanosine triphosphate (GTP)-bound conformation. This effect is reversed by GTPase-activating proteins (GAPs), which stimulate intrinsic Ras GTPase activity, resulting in hydrolysis of bound GTP to GDP and the accumulation of inactive GDP-Ras complexes.2-5 In developing thymocytes, genetic studies have shown that the GEFs, RasGRP, and the Sos-binding protein Grb2 regulate Ras activity in vivo. Inactivation of either RasGRP or Grb2 in mice by homologous recombination results in impaired T-cell development and function because of reduced activation of Ras and its downstream effectors.6,7 However, substantial differences in the thymic phenotype exist between RasGRP and Grb2-deficient mice. RasGRP mice show a 25% reduction in thymic cellularity compared with control mice. They have substantially reduced single-positive (SP) thymocytes. Spleens of these animals contain relatively few mature T cells, consistent with reduced numbers of SP T cells in the thymus. Impaired T-cell development in RasGRP mice is also associated with reduced proliferation and activation of Ras-GTP and extracellular signal-related kinase (ERK) activity in response to T-cell receptor (TCR) stimulation.6 In contrast, Grb2 haploinsufficiency does not affect ERK activity; instead, it attenuates p38 and c-Jun NH2-terminal kinase (JNK) activity in response to TCR stimulation. These biochemical alterations are associated with reduced ability of thymocytes to undergo negative, but not positive, selection.7 Thus, although loss of RasGRP and Grb2 haploinsufficiency in thymocytes results in reduced Ras-GTP, the biologic and biochemical alterations downstream from Ras are quite different. The role of specific GAPs in maintaining overall Ras activity, and consequently the development and function of lymphocytes, has not been investigated. At least 2 GAPs, p120 GAP (also known as Ras-GAP) and neurofibromin (the protein encoded by the Nf1 gene), regulate Ras output in mammalian cells5,8-11 by promoting the conversion of Ras-GTP to Ras-GDP.5 However, their specific role in regulating Ras activity in lymphocytes in vivo is unknown. Mutations of NF1 cause neurofibromatosis type 1 (NF1), an autosomal-dominant disorder with an incidence of 1 in 4000.10-14 Affected individuals are predisposed to the development of benign and malignant neoplasms that arise primarily in cells derived from the embryonic neural crest.10-15 Genetic and biochemical studies have demonstrated that NF1 functions as a tumor suppressor gene by negatively regulating Ras signaling.16-20 Mice that are heterozygous for a targeted disruption of Nf1 (Nf1+/) are predisposed to a number of cancers, including myeloid leukemia.21,22 Leukemic cells from many of these animals show loss of the normal Nf1 allele.21,22 Although mice homozygous for disruption of Nf1 die during embryonic development, adoptive transfer of Nf1/ fetal liver cells into irradiated wild-type (WT) recipients reconstitutes hematopoiesis and results in a myeloproliferative defect.23,24 Further, we have recently shown that Nf1-deficient stem cells demonstrate a growth advantage not only of myeloid cells but also of lymphoid cells in a competitive repopulation assay,25 suggesting a potential role for neurofibromin in lymphocyte development and function. Although substantial recent effort has been made toward understanding the role of Ras in lymphocyte development and function, relatively little is known about the role of GAPs in these processes. In the present study, we have examined the biochemical and functional consequence(s) of Nf1 deficiency in T-cell development and function. We demonstrate that Nf1 deficiency in T cells results in increased thymic and splenic cellularity and an increase in the number of cells in each major T-cell subset. This is associated with impaired proliferation in response to T-cell receptor (TCR) and interleukin-2 receptor (IL-2R) stimulation in vitro. Biochemically, Nf1 deficiency results in elevated basal Ras-GTP levels. In summary, these data demonstrate that neurofibromin functions as a critical negative regulator of Ras and T-cell homeostasis in vivo.     Materials and methods Top Abstract Introduction Materials and methods Results Discussion References Animals Nf1+/ mice were obtained from Dr T. Jacks at the Massachusetts Institute of Technology (Cambridge, MA) in a C57BL/6.129 background and were backcrossed for 13 generations into the C57BL/6J strain. C57BL/6J-recombination activating gene-2 (RAG2)-deficient mice were purchased from Jackson Laboratories (Bar Harbor, ME). These studies were conducted with a protocol approved by the Indiana University Laboratory Animal Research Center. Flow cytometric analysis Phycoerythrin (PE)-conjugated and fluorescein isothiocyanate (FITC)- conjugated monoclonal antibodies (mAbs) against T-cell specific markers, including CD4, CD8, and CD3, were purchased from Invitrogen (Grand Island, NY). Thymocytes and splenocytes were harvested by using standard procedures. Single-cell suspensions were prepared, and 1 × 106 cells of each genotype were incubated at 4°C for 30 minutes with various antibodies. Cells were washed 3 times with phosphate-buffered saline (PBS) containing 0.1% bovine serum albumin (BSA; Sigma), incubated with the second antibody for 30 minutes at 4°C, washed as above, and analyzed by a fluorescence-activated cell sorter (FACS; Becton Dickinson, San Jose, CA). Generation of Nf1/ T cells Heterozygous C57BL/6J Nf1+/ mice were mated to produce Nf1+/+, Nf1+/, and Nf1/ embryos. Pregnant Nf1+/ female mice were killed by cervical dislocation on day 13.5 of gestation, and the embryos were removed and genotyped as previously described.26 Low-density fetal liver cells (5-10 × 106) from Nf1+/+ and Nf1/ littermates were transplanted into syngenic C57BL/6J-RAG2/ recipient mice conditioned with 400 rads of gamma irradiation from Cs source (Gamma cell 40 Extractor; MDS Nordion Kanata, Ontario, Canada) as previously described to facilitate reconstitution.27 In some experiments low-density WT and Nf1/ bone marrow (BM) cells derived from stably reconstituted adult animals with Nf1/ and Nf1+/+ fetal liver cells from embryonic day 13.5 were transplanted into RAG2/ mice. In previous studies, we have demonstrated that hematopoietic stem and progenitor cells (HSPs) derived from the BM of adult mice stably reconstituted with Nf1/ fetal liver cells function similar to fetal liver-derived Nf1/ HSPs following transplantation into irradiated WT recipients.25,26 RAG2/ recipients were killed 2 to 3 months after transplantation as reported previously.27 Spleen and thymus were harvested to compare functional and biochemical consequences of complete loss of Nf1 in thymocytes and mature T cells. In vitro proliferation of T cells To examine the in vitro proliferative capacity of Nf1+/+, Nf1+/, and Nf1/ T cells, thymocytes, splenocytes (2 × 105 cells per well), and purified T cells (1 × 105 cells per well) were stimulated with indicated concentrations (see figure legends for detail) of anti-CD3 (145-2C11; Pharmingen/BD, San Diego, CA) mAb. T cells were purified from spleens of various mice according to manufacturer's instructions (R & D systems, Minneapolis, MN). Briefly, single-cell suspensions were prepared from spleen; red cells were lysed using red cell lysis buffer and resuspended in wash buffer. Cells were then subjected to a T-cell enrichment column and eluted according to the manufacturer's instructions. Purified T cells (1 × 105) were placed in a round-bottom 96-well plate in Iscove modified Dulbecco medium (IMDM) with 10% fetal calf serum (FCS) and 105 M -mercaptoethanol. T cells were stimulated by using plate-bound anti-CD3 mAb and/or interleukin-2 (IL-2) (R & D Systems). Forty-eight hours later cells were pulsed with 1 µCi [3H] thymidine (Amersham Pharmacia Biotech) and harvested 12 hours later to determine the amount of incorporated thymidine. Ras activation assay Freshly isolated thymocytes were lysed in nonionic lysis buffer (20 mM Tris (tris(hydroxymethyl)aminomethane)/HCl, 137 mM NaCl, 1 mM EGTA (ethyleneglycoltetraacetic acid), 1% Triton X-100, 10% glycerol, 1.5 mM MgCl2) and complete protease inhibitors (Amersham Pharmacia Biotech). The protein lysates were equalized for protein concentration by using bicinchoninic acid (BCA) assay (Pierce Chemical), and equal loading of protein in these assays was confirmed by Western blot. Ras activation was subsequently determined by using a Ras activation kit (Upstate Biotechnology) according to the manufacturer's protocol and as previously described.28     Results Top Abstract Introduction Materials and methods Results Discussion References Nf1 heterozygosity results in increased basal Ras activity, thymic cellularity, T-cell subset distribution in vivo, but reduced thymocyte proliferation in vitro Although neurofibromin functions as a GAP for Ras in myeloid cells,23,24 its GAP activity in T cells has not been investigated. To determine whether neurofibromin functions as a GAP for Ras in these cells in vivo, we measured Ras-GTP levels in freshly isolated (unstimulated) thymocytes from WT and Nf1+/ mice. As shown in Figure 1A, Nf1+/ thymocytes demonstrate increased Ras-GTP levels compared with WT control mice. View larger version (16K): [in this window] [in a new window]   Figure 1. Biochemical and functional analysis of WT and Nf1+/ thymocytes. (A) Ras activity of freshly isolated WT (lane 1) and Nf1+/ (lane 2) thymocytes. GTP-bound Ras levels were determined by incubating cell lysates with Raf-1 Ras binding domain (RBD) conjugated to agarose beads and by immunoblotting with an anti-Ras antibody. Immunoblots and quantitative densitometry for Ras-GTP levels and Western blots of total Ras are shown. (B) Thymic cellularity of WT and Nf1+/ mice. Single cell suspensions from WT and Nf1+/ thymi were prepared and counted. Bars represent the absolute numbers of thymocytes (± SEM), n = 12 and * P < .0004. (C) T-cell subset distribution of WT and Nf1+/ thymi. Bars represent the absolute numbers of indicated T-cell subsets (± SEM), n = 12 and * P < .004. (D) Immunocytometric analysis of thymocytes from WT and Nf1+/ mice. Thymocytes from WT and Nf1+/ mice were stained with fluorochrome-conjugated antibodies directed against the indicated cell surface proteins and analyzed by flow cytometry. Data are representative of 5 independent experiments. (E) Altered proliferation of Nf1+/ thymocytes. Thymocytes (105/well) were isolated and activated with plate-bound anti-CD3 mAb, IL-2, or anti-CD3 mAb plus IL-2. Proliferation was measured by a thymidine incorporation assay. Bars denote the mean thymidine incorporation (cpm ± SEM) of a representative experiment performed in replicates of 6. * P < .01 Nf1+/ versus WT. ** P < .01 Nf1+/ versus WT. To investigate the biologic consequence(s) of elevated basal Ras-GTP levels in thymocytes derived from Nf1+/ mice, T-cell development, thymic cellularity, and T-cell maturation were examined and compared with WT mice by using mAbs that recognize T-cell-specific markers unique to different stages of T-cell maturation. As shown in Figure 1B, Nf1+/ mice demonstrate a modest but a substantial increase in thymic cellularity compared with WT control animals. Further, the absolute number of CD4+CD8+ double-positive (DP), CD4+ and CD8+ single-positive (SP), and CD4CD8 double-negative (DN) T-cell subsets were also marginally but substantially elevated in Nf1+/ mice compared with WT control mice (Figure 1C). However, the differentiation of DN thymocytes to DP and SP thymocytes was similar between WT and Nf1+/ mice (Figure 1D). Further, the expression of TCR-CD3 complex as determined by anti-CD3 mAb staining was also similar between WT and Nf1+/ thymocytes (Figure 1D). Thus, elevated basal Ras-GTP levels in Nf1+/ thymocytes result in a marginal but a substantial increase in thymic cellularity and specific thymocyte subsets, without substantially affecting differentiation/maturation as determined by the expression of CD4, CD8, and CD3 cell surface proteins. To determine the effect of elevated basal Ras-GTP levels on the proliferation of Nf1+/ thymocytes in vitro, we examined thymidine incorporation in WT and Nf1+/ thymocytes in response to IL-2 and TCR stimulation. As shown in Figure 1E, stimulation of Nf1+/ thymocytes by anti-CD3 mAb cross-linking of the TCR resulted in proliferation but significantly less compared with WT controls. This decrease was also observed in response to IL-2 stimulation (Figure 1E). Combined stimulation via the T cell and the IL-2 receptor substantially enhanced proliferation in both WT and Nf1+/ thymocytes. However, the increase was less apparent in Nf1+/ thymocytes compared with controls. Interestingly, in spite of the reduced proliferation noted in response to TCR and IL-2R stimulation in Nf1+/ thymocytes, baseline (unstimulated) proliferation of these cells was substantially higher than WT controls. These results suggest that, although TCR- and IL-2R-mediated proliferation is reduced in Nf1+/ thymocytes in vitro, neurofibromin expression is essential for regulating steady state (baseline) proliferation and/or survival of thymocytes in vivo. Nf1 deficiency results in increased thymic cellularity and T-cell subset numbers in vivo but reduced proliferation in vitro Because intercrossing of Nf1+/ mice to produce Nf1-deficient mice results in midgestation embryonic lethality because of cardiac failure, precluding a direct analysis of the consequences of Nf1 deficiency on lymphocyte development and function, RAG2-deficient mice received Nf1/ fetal liver or BM derived stem/progenitor cell transplants to directly asses the role of Nf1 deficiency on T-cell development and function in vivo. In pilot experiments, we determined that the phenotype observed in RAG2/ mice that received Nf1/ BM cells from stably reconstituted adult mice was similar to that observed with Nf1/ fetal liver cells (data not shown). Therefore, in most experiments we used Nf1/ low-density BM cells for transplantation into RAG2/ mice. In RAG2-deficient mice thymocyte development is arrested at the transition from the CD3CD4CD8 to the CD3/low CD4+CD8+ stage,29,30 causing a lack of mature peripheral T cells. This developmental defect can be overcome by introducing WT hematopoietic progenitors in either genetically chimeric mice31 or fetal liver or BM chimera.27 Therefore, RAG2/ mice have been used as a model to study the function of genes that result in mid to late gestation embryonic lethality but are thought to otherwise play an essential role in the development and function of lymphocytes, including T and B cells. As shown in Figure 2A-B, Nf1 deficiency results in significantly greater thymic cellularity compared with control mice. Further, the increase in thymic cellularity was associated with elevated basal Ras-GTP levels (Figure 2C) and an increase in the percentage of thymocytes in the "S" phase of cell cycle (Figure 2D). Consistent with the increase in the number of cells in different T-cell subsets noted in Nf1+/ mice, Nf1 deficiency also resulted in a profound increase in the absolute number of cells in different T-cell subsets, including DP, SP, and DN (Figure 3A). This increase in the absolute number of cells in different T-cell subsets was associated with reduced apoptosis in response to concanavalin A (ConA) stimulation but not dexamethasone or irradiation (data not shown). Interestingly, complete loss of Nf1 did not impair the maturation/differentiation of DN thymocytes to DP and SP subsets as measured by the expression of CD4, CD8, and CD3 (Figure 3B). Taken together, these results demonstrate that neurofibromin does not play a crucial role in regulating T-cell maturation in vivo. View larger version (133K): [in this window] [in a new window]   Figure 2. Nf1 homozygosity results in thymic hyperplasia. (A) Size comparison between WT and Nf1/ thymi. RAG2/ mice that received equal numbers of WT or Nf1/ fetal liver or bone marrow hematopoietic stem and progenitor cells and were killed 2 to 3 months after transplantation. Shown is a representative WT and Nf1/ thymus from a total of 16 analyzed. Original magnification, × 10. (B) Quantitative comparison of thymic cellularity in RAG2/ mice that received WT and Nf1/ fetal liver or bone marrow cells. Single cell suspensions from WT and Nf1/ thymi were prepared and counted. Bars represent the absolute numbers of thymocytes (± SEM) from 13 different mice. * P < .001. (C) Ras activity of freshly isolated WT (lanes 1,2) and Nf1/ (lanes 3,4) thymocytes. GTP-bound Ras levels were determined by incubating cell lysates with Raf-1 RBD conjugated to agarose beads and by immunoblotting with an anti-Ras antibody. Immunoblots and quantitative densitometry for Ras-GTP levels and Western blot for total Ras from 2 separate WT and Nf1/ mice are shown. (D) Cell cycle analysis of WT and Nf1/ thymocytes shown in (A). Single cell suspensions from WT and Nf1/ thymi were stained with propidium iodide and analyzed by flow cytometry, and the percentage of cells from different phases of cell cycle is shown. View larger version (17K): [in this window] [in a new window]   Figure 3. Nf1 homozygosity results in increased thymic T-cell subset numbers but reduced T-cell receptor-mediated proliferation. (A) Comparison of cells in each major T-cell subset between WT cells transplanted into RAG2/ mice (WTRAG2/) and Nf1/ cells transplanted into RAG2/ mice (Nf1/RAG2/) thymus. Bars represent the absolute numbers of indicated T-cell subsets (± SEM), n = 13 and * P < .001. (B) Immunocytometric analysis of thymocytes from WTRAG2/ and Nf1/RAG2/ mice. Cells were stained with fluorochrome-conjugated antibodies directed against the indicated cell surface proteins and analyzed by flow cytometry. Data are representative of 5 independent experiments with similar results. (C) Reduced proliferation of Nf1/ thymocytes. Thymocytes (105/well) were isolated and activated with plate-bound anti-CD3 mAb or anti-CD3 mAb plus IL-2. Proliferation was measured by thymidine incorporation assay. Bars denote the mean thymidine incorporation (cpm ± SEM) of a representative experiment performed in replicates of 6. * P < .01 Nf1/ versus WT. ** P < .01 Nf1/ versus WT. To determine whether Nf1/ thymocytes functionally respond to cytokine or antigen receptor stimulation in vitro, we stimulated WT and Nf1/ thymocytes with either IL-2 or anti-CD3 mAb as described in "Materials and methods." Consistent with the reduced proliferation of Nf1+/ thymocytes in response to IL-2 and anti-CD3 mAb, in vitro stimulation of Nf1/ thymocytes with anti-CD3 mAb is paralleled by a substantial decrease in proliferation compared with controls (Figure 3C). Further, similar to Nf1+/ thymocytes, baseline (unstimulated) proliferation of Nf1/ thymocytes was also substantially higher compared with controls. These results suggest that expression of Nf1 is essential for regulating steady state (baseline) proliferation and/or survival of thymocytes in vivo. Nf1 deficiency results in increased splenic cellularity and T-cell numbers To determine whether the enhanced thymic cellularity in Nf1/ mice also results in elevated numbers of mature T cells in the periphery, we compared the spleens of RAG2/ mice that received either WT or Nf1/ cells. As shown in Figure 4A-B, RAG2/ mice that received Nf1/ fetal liver or BM cells demonstrated splenomegaly and a significant increase in the number of mature T-cell subsets, including CD4 and CD8 SP T cells without affecting differentiation/maturation of these cells (Figure 5A-B). Taken together, these data demonstrate that neurofibromin plays an essential role in the regulation of both mature T-cell numbers in the periphery and immature T-cells numbers in the thymus without affecting differentiation/maturation. View larger version (80K): [in this window] [in a new window]   Figure 4. Nf1 homozygosity results in splenic hyperplasia. (A) Comparison of splenic size between WT and Nf1/ mice. RAG2/ mice received equal numbers of WT or Nf1/ fetal liver or bone marrow hematopoietic stem and progenitor cells and were killed 2 to 3 months after transplantation. Shown are representative WT and Nf1/ spleens from a total of 7 analyzed with similar results. Original magnification, × 10. (B) Quantitative comparison of splenic cellularity in RAG2/ mice that received WT and Nf1/ fetal liver or bone marrow cells. Single cell suspensions from WT and Nf1/ spleens were prepared and counted. Bars represent the absolute numbers of splenocytes (± SEM) from a total of 7 mice of each type. * P < .0005. View larger version (19K): [in this window] [in a new window]   Figure 5. Nf1 homozygosity results in an elevated number of mature T cells in the spleen without altering differentiation. (A) Comparison of CD4 and CD8 SP T-cell numbers between WTRAG2/ and Nf1/RAG2/ spleen. Bars represent the absolute numbers of indicated T-cell subsets (± SEM), n = 7 and * P < .0007. (B) Immunocytometric analysis of splenocytes from RAG2/ (did not receive transplants), WTRAG2/, and Nf1/RAG2/ mice. Splenocytes were stained with fluorochrome-conjugated antibodies directed against the indicated cell surface proteins and analyzed by flow cytometry. Data are representative of 3 independent experiments with similar results. Reduced proliferation in Nf1/ splenocytes and purified T cells To determine whether phenotypically mature Nf1/ T cells proliferate in response to T-cell-specific mitogens, splenocytes and purified T cells from the spleens of WT and Nf1/ mice were stimulated in vitro with anti-CD3 mAb, either alone or in combination with IL-2. As shown in Figure 6A-B and consistent with the reduced proliferation noted above in thymocytes derived from Nf1+/ and Nf1/ mice, mature T cells from Nf1/ mice are also substantially impaired in their ability to incorporate thymidine in response to TCR and IL-2R stimulation. Further, similar to the results observed using Nf1+/ and Nf1/ thymocytes, baseline (unstimulated) proliferation in Nf1/ splenocytes and purified T cells was also marginally but substantially higher compared with controls. These data demonstrate that in spite of relatively normal T-cell maturation in the periphery, neurofibromin deficiency results in impaired in vitro proliferation in response to T-cell-specific mitogens. View larger version (16K): [in this window] [in a new window]   Figure 6. Reduced T-cell receptor-mediated proliferation in Nf1/ splenic T cells. Splenocytes (A) or purified T cells (2 × 105/well) (B) were isolated and activated with plate-bound anti-CD3 mAb or anti-CD3 mAb plus IL-2. Proliferation was measured by thymidine incorporation assay. Bars denote the mean thymidine incorporation (cpm ± SEM) of a representative experiment performed in replicates of 6. ** P < .01 Nf1/ versus WT.     Discussion Top Abstract Introduction Materials and methods Results Discussion References Little is known about the role of neurofibromin in lymphocytes, although neurofibromin is expressed in these cells and is redistributed in response to cross-linking of surface immunoglobulin.32 Further, overexpression of N-Ras in Nf1+/ mice increases the incidence of lymphomas compared with mice carrying a single lesion of either N-Ras or Nf1.33 Additionally, altered immune homeostasis has been described in a patient with a mutation in the NF1 gene.34 More recently, by using a competitive repopulation assay we have demonstrated that Nf1-deficient stem cells show a growth advantage not only in the myeloid lineage but also in the lymphoid lineage.25 However, these studies did not investigate the role of NF1 in the development and function of various T-cell subsets. In the present study, by using Nf1+/ mice and lymphocyte-deficient RAG2/ mice that received Nf1/ hematopoietic cells, we have examined the consequence(s) of inactivating one or 2 alleles of Nf1 in T-cell development and function. We show that neurofibromin regulates T-cell homeostasis in vivo, which is associated with increased basal Ras activity. The use of RAG2/ mice, but not lethally irradiated mice, offers the advantage that the former do not depend on hematopoietic stem cell transfer for their survival because nonlymphocyte lineages are not affected by the mutation. Further, in the absence of competition from endogenous lymphocyte precursors, RAG2/-recipient mice provide a sensitive in vivo system to study lymphopoiesis from hematopoietic precursors. By using these mice, our results demonstrate that loss of Nf1 results in a lymphoproliferative defect both in immature and mature T-cell compartments. This defect is associated with elevated levels of basal Ras-GTP in developing thymocytes, identifying neurofibromin as a mammalian GAP for Ras in T cells. Although novel with respect to T cells, previous studies have clearly shown that NF1 regulates myeloid cell proliferation, in part by regulating Ras activity.23,24 Specifically, hematopoietic progenitors derived from patients with NF1, or mice lacking the expression of Nf1 are hypersensitive to granulocyte-macrophage colony-stimulating factor (GM-CSF) and stem cell factor (SCF), which is associated with elevated levels of basal Ras-GTP.23-26 Consistent with a role for NF1 function as a GAP for Ras in myeloid cells, expression of the GAP-related domain of NF1 in Nf1/ hematopoietic cells is sufficient to correct the hypersensitivity to growth factors associated with these cells in vitro.35 The observation that neurofibromin regulates decreased induced proliferation in thymocytes is consistent with previous studies comparing Ras-GTP levels in embryonic cell lines derived from mice deficient in the expression of p120-GAP or neurofibromin.36 The p120-GAP mutant cell lines from E9.5 embryos are more sensitive than WT cells to growth factor-induced changes in Ras-GTP levels.36 In contrast, Nf1-deficient E9.5 embryonic cell lines do not demonstrate a substantial increase in Ras-GTP levels in response to growth factor stimulation but exhibit a higher basal level of Ras-GTP.36 These results suggest that p120-GAP may function to down-regulate Ras molecules that have been activated by growth factor receptors, whereas neurofibromin may play an essential role in regulating basal Ras-GTP levels.36,37 Consistent with these findings, p120-GAP/ and Nf1/ mouse embryos have distinct phenotypes. Embryos homozygous for both mutations have a phenotype much more severe than that seen by either mutation alone,37 suggesting that p120-GAP and neurofibromin may have independent biologic functions but synergize to regulate Ras output.37 Consistent with several reports that demonstrate altered biologic responses in multiple cell types because of loss of one Nf1 allele,38-45 loss of a single Nf1 allele was also sufficient in modulating Ras activity in unstimulated thymocytes, which correlated with a modest but a substantial increase in T-cell subset numbers in Nf1+/ mice. The increase in the T-cell subset numbers was, however, more apparent in thymocytes and splenocytes lacking the expression of both Nf1 alleles. Interestingly, despite the increase in the total number of thymocytes in Nf1+/ and Nf1/ mice in vivo, stimulation of these cells via the TCR and/or the IL-2 receptor resulted in a substantial decrease in proliferation in vitro, although the proliferation of unstimulated Nf1+/ and Nf1/ T cells was substantially higher compared with WT controls. The reason for this apparent paradox is unclear, although similar lymphoproliferative defects have been reported in other systems. Specifically, mice deficient in the expression of IL-2R or Stat5a/b develop a lymphoproliferative defect similar to that observed in Nf1/ mice.46,47 T cells in Stat5a/b- and IL-2R-deficient mice develop normally; however, they fail to proliferate in vitro in response to IL-2 and TCR cross-linking.46,47 Interestingly, both IL-2R- and Stat5a/b-deficient mice also develop splenomegaly, similar to that observed in Nf1/ mice. The lack of proliferation in Stat5a/b-deficient mice is due to lack of induction of expression of cell cycle-related genes in response to TCR and IL-2R stimulation.46 Whether similar defects exist in Nf1/ T cells needs to be investigated. Several studies have suggested a role for Ras and its downstream effectors in regulating T-cell development and function, including Raf, mitogen-induced extracellular kinase (MEK), and ERK.48-53 However, most of these studies used dominant-negative and/or activated forms of kinases.48-52 Although informative, these studies do not clearly reflect the physiologic consequence(s) of altered Ras activity on T-cell development and function in vivo. In the present study, we show that Nf1 deficiency results in increased numbers of immature and mature T cells in vivo, which is associated with reduced in vitro proliferation in response to TCR and IL-2R stimulation. This phenotype correlates with elevated basal Ras activity. To our knowledge these are the first studies describing the in vivo and in vitro consequences of impaired GAP activity on T-cell development and function.     Note added in proof Kim et al54 recently reported a similar reduction in Nf1/ B lymphocytes and thymocyte proliferation in vitro.     Acknowledgments We thank Drs Merv Yoder and Mark Kaplan for their helpful discussions and suggestions on the manuscript. We thank Marsha Hippensteel for her help with manuscript preparation.     Footnotes Submitted March 8, 2002; accepted June 3, 2002. Prepublished online as Blood First Edition Paper, July 5, 2002; DOI 10.1182/blood-2002-03-0734. Supported by the National Institutes of Health grant R29 CA74177 (D.W.C.), Department of Defense grant NF000035 (D.W.C.), and by the National Institute of Health Pediatric Scientist Development Program Grant K12-HD0050 (D.A.I.). R.K. is a recipient of the American Society of Hematology Junior Faculty Scholar Award. The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734. Reprints: Reuben Kapur, Herman B. Wells Center for Pediatric Research, Cancer Research Bldg, 1044 W Walnut St, Rm 425, Indianapolis, IN 46202; e-mail: rkapur{at}iupui.edu.     References Top Abstract Introduction Materials and methods Results Discussion References 1. Genot E, Cantrell DA. Ras regulation and function in lymphocytes. Curr Opin Immunol. 2000;12:289-294[CrossRef][Medline] [Order article via Infotrieve]. 2. Bourne HR, Sanders DA, McCormick F. The GTPase superfamily: a conserved switch for diverse cell functions. Nature. 1990;348:125-132[CrossRef][Medline] [Order article via Infotrieve]. 3. Bourne HR, Sanders DA, McCormick F. The GTPase superfamily: conserved structure and molecular mechanism. Nature. 1991;349:117-127[CrossRef][Medline] [Order article via Infotrieve]. 4. Hall A. The cellular functions of small GTP-binding proteins. Science. 1990;249:635-640[Abstract/Free Full Text]. 5. Hall A. Signal transduction through small GTPasesa tale of two GAPs. Cell. 1992;69:389-391[CrossRef][Medline] [Order article via Infotrieve]. 6. Dower NA, Stang SL, Bottorff DA, et al. RasGRP is essential for mouse thymocyte differentiation and TCR signaling. Nat Immunol. 2000;1:317-321[CrossRef][Medline] [Order article via Infotrieve]. 7. Gong Q, Cheng AM, Akk AM, et al. Disruption of T cell signaling networks and development by Grb2 haploid insufficiency. Nat Immunol. 2001;2:29-36[CrossRef][Medline] [Order article via Infotrieve]. 8. Boguski MS, McCormick F. Proteins regulating Ras and its relatives. Nature. 1993;366:643-654[CrossRef][Medline] [Order article via Infotrieve]. 9. Clark GJ, Drugan JK, Terrell RS, et al. Peptides containing a consensus Ras binding sequence from Raf-1 and the GTPase activating protein NF1 inhibit Ras function. Proc Natl Acad Sci U S A. 1996;93:1577-1581[Abstract/Free Full Text]. 10. DeClue JE, Papageorge AG, Fletcher JA, et al. Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell. 1992;69:265-273[CrossRef][Medline] [Order article via Infotrieve]. 11. Xu GF, O'Connell P, Viskochil D, et al. The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell. 1990;62:599-608[CrossRef][Medline] [Order article via Infotrieve]. 12. Legius E, Marchuk DA, Collins FS, Glover TW. Somatic deletion of the neurofibromatosis type 1 gene in a neurofibrosarcoma supports a tumour suppressor gene hypothesis. Nat Genet. 1993;3:122-126[CrossRef][Medline] [Order article via Infotrieve]. 13. Menon AG, Anderson KM, Riccardi VM, et al. Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis. Proc Natl Acad Sci U S A. 1990;87:5435-5439[Abstract/Free Full Text]. 14. Skuse GR, Kosciolek BA, Rowley PT. Molecular genetic analysis of tumors in von Recklinghausen neurofibromatosis: loss of heterozygosity for chromosome 17. Genes Chromosomes Cancer. 1989;1:36-41[Medline] [Order article via Infotrieve]. 15. Johnson MR, Look AT, DeClue JE, Valentine MB, Lowy DR. Inactivation of the NF1 gene in human melanoma and neuroblastoma cell lines without impaired regulation of GTP.Ras. Proc Natl Acad Sci U S A. 1993;90:5539-5543[Abstract/Free Full Text]. 16. Brodeur GM. The NF1 gene in myelopoiesis and childhood myelodysplastic syndromes. N Engl J Med. 1994;330:637-639[Free Full Text]. 17. Side L, Taylor B, Cayouette M, et al. Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders. N Engl J Med. 1997;336:1713-1720[Abstract/Free Full Text]. 18. Neubauer A, Shannon K, Liu E. Mutations of the ras proto-oncogenes in childhood monosomy 7. Blood. 1991;77:594-598[Abstract/Free Full Text]. 19. Shannon KM, Watterson J, Johnson P, et al. Monosomy 7 myeloproliferative disease in children with neurofibromatosis, type 1: epidemiology and molecular analysis. Blood. 1992;79:1311-1318[Abstract/Free Full Text]. 20. Shannon KM, O'Connell P, Martin GA, et al. Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. N Engl J Med. 1994;330:597-601[Abstract/Free Full Text]. 21. Jacks T, Shih TS, Schmitt EM, Bronson RT, Bernards A, Weinberg RA. Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. Nat Genet. 1994;7:353-361[CrossRef][Medline] [Order article via Infotrieve]. 22. Brannan CI, Perkins AS, Vogel KS, et al. Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues. Genes Dev. 1994;8:1019-1029[Abstract/Free Full Text]. 23. Largaespada DA, Brannan CI, Jenkins NA, Copeland NG. Nf1 deficiency causes Ras-mediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia. Nat Genet. 1996;12:137-143[CrossRef][Medline] [Order article via Infotrieve]. 24. Bollag G, Clapp DW, Shih S, et al. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet. 1996;12:144-148[CrossRef][Medline] [Order article via Infotrieve]. 25. Zhang Y, Taylor BR, Shannon K, Clapp DW. Quantitative effects of Nf1 inactivation on in vivo hematopoiesis. J Clin Invest. 2001;108:709-715[CrossRef][Medline] [Order article via Infotrieve]. 26. Zhang YY, Vik TA, Ryder JW, et al. Nf1 regulates hematopoietic progenitor cell growth and ras signaling in response to multiple cytokines. J Exp Med. 1998;187:1893-1902[Abstract/Free Full Text]. 27. Rodewald HR, Kretzschmar K, Takeda S, Hohl C, Dessing M. Identification of pro-thymocytes in murine fetal blood: T lineage commitment can precede thymus colonization. EMBO J. 1994;13:4229-4240[Medline] [Order article via Infotrieve]. 28. Gille H, Downward J. Multiple ras effector pathways contribute to G(1) cell cycle progression. J Biol Chem. 1999;274:22033-22040[Abstract/Free Full Text]. 29. Shinkai Y, Rathbun G, Lam KP, et al. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell. 1992;68:855-867[CrossRef][Medline] [Order article via Infotrieve]. 30. Mombaerts P, Iacomini J, Johnson RS, Herrup K, Tonegawa S, Papaioannou VE. RAG-1-deficient mice have no mature B and T lymphocytes. Cell. 1992;68:869-877[CrossRef][Medline] [Order article via Infotrieve]. 31. Chen J, Lansford R, Stewart V, Young F, Alt FW. RAG-2-deficient blastocyst complementation: an assay of gene function in lymphocyte development. Proc Natl Acad Sci U S A. 1993;90:4528-4532[Abstract/Free Full Text]. 32. Boyer MJ, Gutmann DH, Collins FS, Bar-Sagi D. Crosslinking of the surface immunoglobulin receptor in B lymphocytes induces a redistribution of neurofibromin but not p120-GAP. Oncogene. 1994;9:349-357[Medline] [Order article via Infotrieve]. 33. Mangues R, Corral T, Lu S, Symmans WF, Liu L, Pellicer A. NF1 inactivation cooperates with N-ras in in vivo lymphogenesis activating Erk by a mechanism independent of its Ras-GTPase accelerating activity. Oncogene. 1998;17:1705-1716[CrossRef][Medline] [Order article via Infotrieve]. 34. Cooper LJ, Shannon KM, Loken MR, Weaver M, Stephens K, Sievers EL. Evidence that juvenile myelomonocytic leukemia can arise from a pluripotential stem cell. Blood. 2000;96:2310-2313[Abstract/Free Full Text]. 35. Hiatt KK, Ingram DA, Zhang Y, Bollag G, Clapp DW. Neurofibromin GTPase-activating protein-related domains restore normal growth in Nf1/ cells. J Biol Chem. 2001;276:7240-7245[Abstract/Free Full Text]. 36. van der Geer P, Henkemeyer M, Jacks T, Pawson T. Aberrant Ras regulation and reduced p190 tyrosine phosphorylation in cells lacking p120-Gap. Mol Cell Biol. 1997;17:1840-1847[Abstract]. 37. Henkemeyer M, Rossi DJ, Holmyard DP, et al. Vascular system defects and neuronal apoptosis in mice lacking ras GTPase-activating protein. Nature. 1995;377:695-701[CrossRef][Medline] [Order article via Infotrieve]. 38. Ingram DA, Yang FC, Travers JB, et al. Genetic and biochemical evidence that haploinsufficiency of the Nf1 tumor suppressor gene modulates melanocyte and mast cell fates in vivo. J Exp Med. 2000;191:181-188[Abstract/Free Full Text]. 39. Ingram DA, Hiatt K, King AJ, et al. Hyperactivation of p21(ras) and the hematopoietic-specific Rho GTPase, Rac2, cooperate to alter the proliferation of neurofibromin-deficient mast cells in vivo and in vitro. J Exp Med. 2001;194:57-69[Abstract/Free Full Text]. 40. Gutmann DH, Wu YL, Hedrick NM, Zhu Y, Guha A, Parada LF. Heterozygosity for the neurofibromatosis 1 (NF1) tumor suppressor results in abnormalities in cell attachment, spreading and motility in astrocytes. Hum Mol Genet. 2001;10:3009-3016[Abstract/Free Full Text]. 41. Bajenaru ML, Donahoe J, Corral T, et al. Neurofibromatosis 1 (NF1) heterozygosity results in a cell-autonomous growth advantage for astrocytes. Glia. 2001;33:314-323[CrossRef][Medline] [Order article via Infotrieve]. 42. Gutmann DH, Loehr A, Zhang Y, Kim J, Henkemeyer M, Cashen A. Haploinsufficiency for the neurofibromatosis 1 (NF1) tumor suppressor results in increased astrocyte proliferation. Oncogene. 1999;18:4450-4459[CrossRef][Medline] [Order article via Infotrieve]. 43. Atit RP, Crowe MJ, Greenhalgh DG, Wenstrup RJ, Ratner N. The Nf1 tumor suppressor regulates mouse skin wound healing, fibroblast proliferation, and collagen deposited by fibroblasts. J Invest Dermatol. 1999;112:835-842[CrossRef][Medline] [Order article via Infotrieve]. 44. Costa RM, Federov NB, Kogan JH, et al. Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1. Nature. 2002;415:526-530[CrossRef][Medline] [Order article via Infotrieve]. 45. Cichowski K, Jacks T. NF1 tumor suppressor gene function: narrowing the GAP. Cell. 2001;104:593-604[CrossRef][Medline] [Order article via Infotrieve]. 46. Moriggl R, Topham DJ, Teglund S, et al. Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells. Immunity. 1999;10:249-259[CrossRef][Medline] [Order article via Infotrieve]. 47. Suzuki H, Kundig TM, Furlonger C, et al. Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta. Science. 1995;268:1472-1476[Abstract/Free Full Text]. 48. Alberola-Ila J, Forbush KA, Seger R, Krebs EG, Perlmutter RM. Selective requirement for MAP kinase activation in thymocyte differentiation. Nature. 1995;373:620-623[CrossRef][Medline] [Order article via Infotrieve]. 49. Gartner F, Alt FW, Monroe R, et al. Immature thymocytes employ distinct signaling pathways for allelic exclusion versus differentiation and expansion. Immunity. 1999;10:537-546[CrossRef][Medline] [Order article via Infotrieve]. 50. Iritani BM, Alberola-Ila J, Forbush KA, Perimutter RM. Distinct signals mediate maturation and allelic exclusion in lymphocyte progenitors. Immunity. 1999;10:713-722[CrossRef][Medline] [Order article via Infotrieve]. 51. Swat W, Shinkai Y, Cheng HL, Davidson L, Alt FW. Activated Ras signals differentiation and expansion of CD4+8+ thymocytes. Proc Natl Acad Sci U S A. 1996;93:4683-4687[Abstract/Free Full Text]. 52. Crompton T, Gilmour KC, Owen MJ. The MAP kinase pathway controls differentiation from double-negative to double-positive thymocyte. Cell. 1996;86:243-251[CrossRef][Medline] [Order article via Infotrieve]. 53. Pages G, Guerin S, Grall D, et al. Defective thymocyte maturation in p44 MAP kinase (Erk 1) knockout mice. Science. 1999;286:1374-1377[Abstract/Free Full Text]. 54. Kim TJ, Cariappa A, Iacomini J, et al. Defective proliferative responses in B lymphocytes and thymocytes that lack neurofibromin. Mol Immunol. 2002;38:701-708[CrossRef][Medline] [Order article via Infotrieve]. © 2002 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: F. Guo, J. A. Cancelas, D. Hildeman, D. A. Williams, and Y. Zheng Rac GTPase isoforms Rac1 and Rac2 play a redundant and crucial role in T-cell development Blood, September 1, 2008; 112(5): 1767 - 1775. [Abstract] [Full Text] [PDF] H. Chen, Y. Qiu, L. Chen, L. Li, J. Chen, C. Zhang, B. Wang, Y. Yu, Z. Zhu, F. Zhu, et al. The Expression of Neurofibromin in Human Osteoblasts and Chondrocytes Ann. Clin. Lab. Sci., January 1, 2008; 38(1): 25 - 30. [Abstract] [Full Text] [PDF] G. Yang, W. Khalaf, L. van de Locht, J. H. Jansen, M. Gao, M. A. Thompson, B. A. van der Reijden, D. H. Gutmann, R. Delwel, D. W. Clapp, et al. Transcriptional Repression of the Neurofibromatosis-1 Tumor Suppressor by the t(8;21) Fusion Protein Mol. Cell. Biol., July 15, 2005; 25(14): 5869 - 5879. [Abstract] [Full Text] [PDF] D. T. Le, N. Kong, Y. Zhu, J. O. Lauchle, A. Aiyigari, B. S. Braun, E. Wang, S. C. Kogan, M. M. Le Beau, L. Parada, et al. Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder Blood, June 1, 2004; 103(11): 4243 - 4250. [Abstract] [Full Text] [PDF] This Article Abstract Full Text (PDF) All Versions of this Article: 2002-03-0734v1 100/10/3656    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Ingram, D. A. Articles by Kapur, R. Search for Related Content PubMed PubMed Citation Articles by Ingram, D. A. Articles by Kapur, R. Related Collections Hematopoiesis and Stem Cells Immunobiology Social Bookmarking                   What's this?

	Copyright © 2002 by American Society of Hematology         Online ISSN: 1528-0020